Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivantamab + lazertinib versus osimertinib versus lazertinib in first-line EGFR-mutated advanced or metastatic NSCLC
2020-000743-31Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2020
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of amivantamab, lazertinib and osimertinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Progression-free survival. Started Jun 2020; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2020-000743-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000743-31.